On the afternoon of January 29th, the official account of the National Health Insurance Bureau sent a reply to the " " suspect who had been suspected of cheating the medical insurance fund. The suspect has been arrested for .
According to the announcement, in August 2021, AstraZeneca found in its internal compliance inspection that a small number of employees in Shenzhen tampered with or participated in tampering with the patient's test report, suspected of defrauding the medical insurance fund . According to the compliance policy, AstraZeneca dealt with these employees who violated the company's rules and regulations seriously, took the initiative to report to the local medical insurance department at the first time, showed the company's attitude, and actively assisted the government in the investigation.
On December 27, 2021, the national medical insurance bureau and the Ministry of Public Security jointly interviewed AstraZeneca China. At the meeting, relevant departments introduced the investigation of suspected insurance fraud in Shenzhen and put forward relevant improvement suggestions.
In this regard, AstraZeneca said: "it will continue to carry out targeted internal self inspection and self correction actions to prevent any suspected insurance fraud and other violations of law and discipline".
It is worth noting that the document issued by the medical insurance bureau also mentioned that "AstraZeneca China, in accordance with the interview requirements, timely connected with the Shenzhen medical insurance bureau and the public security bureau to do a good job in the follow-up investigation of the case, urged employees who have similar behaviors to voluntarily surrender, and announced the case and self-examination and rectification on the enterprise's official website"
AstraZeneca: trillion market value multinational pharmaceutical giant
According to public information, AstraZeneca is the world's leading pharmaceutical company, which was merged by the former Astra company in Sweden and the former British AstraZeneca company in 1999. As a global biopharmaceutical enterprise driven by innovation, AstraZeneca is headquartered in London, UK, with about 61500 employees around the world, business in more than 100 countries, and the company has set up production bases in 17 countries. The three strategic R & D centers are located in Cambridge, England, Gaithersburg, Maryland and Mondale, Sweden, with an annual R & D investment of more than US $4 billion.
AstraZeneca entered China in 1993. China is headquartered in Shanghai and has more than 10000 employees across the country. In China, AstraZeneca's business focus is mainly on the treatment areas most needed by Chinese patients, including cardiovascular, metabolic diseases, tumors, respiratory, digestive and kidney diseases.
In addition to its Shanghai headquarters, AstraZeneca has also established regional headquarters in Beijing, Guangzhou, Wuxi, Hangzhou and Chengdu. The company has invested and built production bases in Wuxi and Taizhou, Jiangsu, and established a Chinese logistics center in Wuxi. In 2017, China Health Internet of things innovation center was launched in Wuxi to explore innovative integrated whole course management solutions for health Internet of things diagnosis and treatment. In the same year, AstraZeneca and SDIC innovation jointly established Dizhe (Jiangsu) Pharmaceutical Co., Ltd. to accelerate the pace of local new drug research and development. In 2019, AstraZeneca announced to cooperate with Wuxi to build Wuxi International Life Science Innovation Park, bringing together global wisdom and benefiting Chinese patients. In the same year, AstraZeneca announced the establishment of a global R & D China Center in Shanghai and the establishment of a global medical industry fund. In 2020, AstraZeneca announced its support for the "Internet hospital" project.
AstraZeneca's 2020 annual report shows that its total revenue is US $26.617 billion, a year-on-year increase of 9%. Among them, the revenue of China is US $5.375 billion, accounting for 20.2% of AstraZeneca's global revenue. Although the growth rate is significantly lower than that in 2019 (10% vs 35%) due to the covid-19 epidemic, medical insurance negotiation and the reduction of drug prices with volume procurement, it is still the best performing multinational pharmaceutical enterprise in the Chinese market.
On December 8, 2021, the company announced that the AstraZeneca long-acting antibody (laab) combination evusheld (a combination of tixagevimab and cilgavimab) has been authorized by the United States for emergency use (EUA) for the prevention of covid-19 pneumonia before exposure, and the first batch of drugs will be on the market soon.
As of the latest, its market value is $183.8 billion, about 1169 billion yuan.
